https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Tarlatamab Combination Regimen Demonstrates Potential as Maintenance Therapy in ES-SCLC

Tarlatamab Combination Regimen Demonstrates Potential as Maintenance Therapy in ES-SCLC

When combined with an anti–PD-L1 therapy, tarlatamab significantly improves overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

administrator

Related Articles